Amino cyclobutylamide modulators of chemokine receptor activity

An alkyl, phenyl technology, applied in the field of aminocyclobutylamide modulators of chemokine receptor activity, can solve the problem of poor sensitivity of rheumatoid arthritis

Inactive Publication Date: 2006-06-14
MERCK & CO INC
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among persons homozygous for a 32-base pair deletion in the CCR-5 gene, there appears to be poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amino cyclobutylamide modulators of chemokine receptor activity
  • Amino cyclobutylamide modulators of chemokine receptor activity
  • Amino cyclobutylamide modulators of chemokine receptor activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0641]

[0642] Step A

[0643]

[0644] Intermediate 1 (200 mg, 1.75 mmol), bis(trifluoromethyl)benzylamine (490 mg, 1.75 mmol), DIEA (306 μL, 1.75 mmol), HOAT (240 mg, 1.75 mmol), EDC (504 mg, 2.63 mmol) Combined with DCM (15ml) and stirred at room temperature for 18 hours. The reaction mixture was diluted with DCM, washed with 1N HCl, saturated NaHCO 3 solution, water and brine, washed with anhydrous MgSO 4 Drying and concentration in vacuo afforded the product (529mg, 89%).

[0645] NMR (300MHz, CDCl 3 )δ7.81(s, 1H), 7.74(s, 2H), 6.13(s, 1H), 4.62(d, J=6.04Hz, 2H), 3.56-3.47(m, 2H), 3.29-3.20(m , 2H), 3.07(m, 1H).

[0646] Step B

[0647]

[0648] The product from Step A (100 mg, 0.295 mmol), Intermediate 2 (70 mg, 0.295 mmol), DIEA (103 μL, 0.590 mmol), molecular sieves, NaBH(OAc) 3 (313, 1.474mmol) and DCE (10ml) were mixed together and stirred at room temperature for 18 hours. The reaction was purified by prep...

Embodiment 11

[0655]

[0656] Step A

[0657]

[0658] Intermediate 3 (100 mg, 0.49 mmol), Intermediate 2 (116 mg, 0.49 mmol), DIEA (171 μL, 0.98 mmol), molecular sieves, NaBH(OAc) 3 (520mg, 2.45mmol) and DCM (10ml) were mixed together and stirred at room temperature for 60 hours. The reaction was purified by preparative TLC (2:0.2:97.8, MeOH:NH 4OH:DCM) to give the product (95 mg, 50%). LC-MS for C 26 h 29 NO 2 MW: The calculated value is 387.22, and the measured value is 388.15.

[0659] Step B

[0660]

[0661] The product from step A (90 mg, 0.232 mmol), 5N NaOH solution (325 μL, 1.63 mmol), EtOH (3 ml) and water (2.65 ml) were mixed together and stirred at room temperature. After disappearance of starting material, the reaction mixture was concentrated in vacuo and redissolved in water. The aqueous layer was neutralized to pH 7.0 with 2N HCl solution, then extracted with DCM (7x). The organic layer contained mostly benzyl alcohol. The aqueous layer was concentrated a...

Embodiment 12

[0666]

[0667] Step A

[0668]

[0669] A solution of 60% NaH (10 g, 250 mmol) suspended in DMF (100 ml) was cooled to 0° C., then benzyl cyanide (11.7 g, 100 mmol) was slowly added. The solution was stirred at 0°C for an additional 10 minutes, then dimethoxy-dibromomethane (13.1 g, 50 mmol) was added. The reaction mixture was stirred at 60°C for 18 hours, then cooled to room temperature, poured into water and extracted with ether. The combined organic layers were concentrated in vacuo. The crude product was purified by flash chromatography (20:80, ethyl acetate:hexanes) to give the desired product (6.4 g, 59%).

[0670] NMR (300MHz, CDCl3) δ7.50-7.32(m, 5H), 3.23(d, J=30.6Hz, 6H), 3.11(dm, J=13.6Hz, 2H), 2.73(dm, J=11.7Hz, 2H).

[0671] Step B

[0672]

[0673] A solution of the product from Step A (4.4g, 20mmol), 5M NaOH (20ml), EtOH (50ml) and water (50ml) was heated at reflux overnight then concentrated to dryness. The concentrate was redissolved in water (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compounds of formula I and II, which can be used as modulators of chemokine receptor activity, in particular, these compounds can be used as modulators of chemokine receptor CCR-2. Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R25, R26, Y, Z, 1, m, n and dashed lines are as in the description of the present invention defined in.

Description

Background of the invention [0001] Chemokines are a family of small (70-120 amino acids) proinflammatory cytokines with potent chemotactic activity. Chemokines are chemotactic cytokines released by various cells to attract the arrival of different cells such as monocytes, macrophages, T cells, eosinophils, basophils and neutrophils Site of inflammation (for review see Schall, Cytokine , 3, 165-183 (1991) and Murphy, Rev. Immun. , 12, 593-633 (1994)). These molecules were originally defined by 4 retained cysteines and were divided into two subfamilies according to the arrangement of the first pair of cysteines. In CXC-chemokine families including IL-8, GROα, NAP-2 and IP-10, the two cysteines are separated by one amino acid, whereas in CXC-chemokine families including RANTES, MCP-1, MCP- 2. In the CC-chemokine family including MCP-3, MIP-1α, MIP-1β and eotaxin, these two residues are adjacent. [0002] α-Chemokines, such as interleukin-8 (IL-8), neutrophil-activated prote...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/44C07D211/14C07D211/18C07D211/42C07D211/52C07D211/58C07D211/64C07D211/70C07D221/20C07D295/155C07D309/14C07D401/04C07D401/08C07D401/12C07D405/12C07D471/04C07D471/10
CPCA61P3/06A61P9/10A61P17/00A61P19/02A61P27/02A61P27/16A61P29/00A61P37/02A61P37/08A61P43/00C07D211/14C07D211/18C07D211/42C07D211/52C07D211/58C07D211/64C07D211/70C07D221/20C07D295/155C07D309/14C07D401/04C07D401/08C07D401/12C07D405/12C07D471/04C07D471/10
Inventor R·焦杨立虎
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products